Superworth

Oruka Therapeutics EPS ORKA

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$2.12
Latest quarter, Q2 FY26
−$0.55
Fiscal year 2025
−$1.95

Oruka Therapeutics' earnings per share was −$2.12 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.55.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.95n/a
FY2023−$4.44n/a
FY2022−$8.28n/a
FY2021−$16.68n/a
FY2020−$29.28n/a
FY2019−$54.36n/a
FY2018−$123.96n/a
FY2017−$393.12n/a
FY2016−$390.96n/a
FY2015−$488.16n/a
FY2014−$712.80n/a
FY2013−$2041.20n/a
FY2012−$3024.00n/a
FY2011−$4898.88n/a
FY2010n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.55n/a−$2.12
Q1 FY26−$0.48n/a−$2.03
Q4 FY25−$0.54n/a−$1.95
Q3 FY25−$0.55n/an/a
Q2 FY25−$0.46n/an/a
Q1 FY25−$0.40n/an/a
Q3 FY24−$1.46n/a−$11.06
Q2 FY24−$6.96n/a−$10.80
Q1 FY24−$1.68n/a−$5.04
Q4 FY23−$0.96n/a−$4.44
Q3 FY23−$1.20n/a−$4.44
Q2 FY23−$1.20n/a−$5.16

Against its peers

Companies in Drug Manufacturers - General nearest Oruka Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
ORKAOruka Therapeutics−$2.12
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
LGNDLigand Pharmaceuticals$9.40
AMRXAmneal Pharmaceuticals$0.49+4800% a year
INDVIndivior Pharmaceuticals$2.78+227% a year
ARQTArcutis Biotherapeutics$0.22
ALKSAlkermes plc.$0.38−82% a year
LQDALiquidia$1.39
OGNOrganon$0.77−71% a year
TGTXTG Therapeutics$2.74+641% a year
PTGXProtagonist Therapeutics$1.03+47% a year
Peer median$1.00

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Oruka Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.